Tuesday, February 21, 2017

Drugs in Clinical Pipeline: SC-006 | Treatment of Colorectal Cancer (CRC)

SC-006 is an experimental drug being developed by AbbVie in collaboration with Stemcentrx, for treating patients with advanced colorectal cancer (CRC).

Treatment of Colorectal Cancer
New Drug for Treating Colorectal Cancer
AbbVie, a global biopharmaceutical company, announced in April 2016 that it will acquire Stemcentrx to further boost it’s oncology pipeline. SC-006 is a fruit of the merger. Though the mechanism of action is not revealed, it could be directed against DLL3 (delta-like protein 3) like SC-002.
SC-006 is in Phase I clinical trials in patients with CRC as an intravenous dose regime.

1. ClinicalTrials.gov A Study of SC-006 in Subjects With Advanced Cancer. NCT03035279
1 2 3